Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Breast 4Dermatologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 63Cyclophosphamide 55Radiotherapy 53Bevacizumab 50Doxorubicin 48Ifosfamide 33pazopanib 28fludarabine phosphate 28Etoposide 27Radiation 24Gemcitabine 24pembrolizumab 23Sirolimus 23Sunitinib 22Filgrastim 22Irinotecan 21Whole-Body Irradiation 20Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 20Imatinib Mesylate 20Vincristine 19Magnetic Resonance Spectroscopy 18Sorafenib 16Methotrexate 16Busulfan 16Melphalan 15Carboplatin 15Docetaxel 14Cyclosporine 14temsirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Mental Status and Dementia Tests × Sarcoma × Clear all
NCT00731731 2022-08-04

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
125 enrolled 12 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡